54: Outcomes of Extracorporeal Membrane Oxygenation in Cardiorespiratory Failure: A single Centre Retrospective Study

Introduction: ECMO has become an essential tool in the management of complex cardiorespiratory failure when other interventions fail. This study provides survival and outcomes data from our center. Methods: We retrospectively reviewed cases from August 2022 to September 2024. Baseline characteristics of patients, ECMO type and indication, scoring systems, time to initiation, hospital days, ICU days, ECMO duration, successful weaning and survival rate were assessed. Results: 22 cases were identified with various indications majority being VA ECMO (68%) secondary to cardiogenic shock SCAI D->E(60%), while VV ECMO (32%) was used for severe ARDS (100%). Mean age of the patients was 47.68 ± 13.97 years with male preponderance (68%). eCPR was done in two patients out of which one patient survived to discharge, while one patient on VV ECMO required proning on ECMO. All cannulations were percutaneous (90.9%), done in cath lab except for 2 where one had morbid obesity and second had high bifurcation. Mean duration was 6.14 ± 4.29 days. Most common cause of death in VV ECMO were new onset biventricular dysfunction and bowel ischemia, while in VA ECMO it was poor neurological performance. 59% were successfully weaned and decannulated, however only 54.5% were discharged home. Scoring systems used to prognosticate were RESP, PRESERVE, and PRESET in VV, and SAVE and PREDICT -VA in VA ECMO. The most frequently observed complication was deep vein thrombosis (28.57%). When analyzed by year of cannulation, survival improved over time in both modalities. (Fig 1) Conclusions: Survival rates with ECMO for variable indications are increasing over time with cumulating experiences and techniques.